CalciMedica (NASDAQ:CALC) Earns “Buy” Rating from HC Wainwright

CalciMedica (NASDAQ:CALC)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $16.00 target price on the stock. HC Wainwright also issued estimates for CalciMedica’s Q4 2025 earnings at ($0.48) EPS.

CalciMedica Stock Performance

NASDAQ CALC opened at $1.85 on Tuesday. The firm’s 50 day moving average price is $2.32 and its two-hundred day moving average price is $3.11. CalciMedica has a twelve month low of $1.81 and a twelve month high of $6.27. The stock has a market cap of $24.94 million, a price-to-earnings ratio of -1.71 and a beta of 1.20.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.14. On average, research analysts forecast that CalciMedica will post -2.21 EPS for the current fiscal year.

Institutional Trading of CalciMedica

Institutional investors have recently made changes to their positions in the stock. Cetera Investment Advisers lifted its position in CalciMedica by 37.1% in the 4th quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock worth $60,000 after buying an additional 4,566 shares in the last quarter. Atria Investments Inc increased its stake in shares of CalciMedica by 28.3% in the fourth quarter. Atria Investments Inc now owns 34,012 shares of the company’s stock worth $120,000 after acquiring an additional 7,509 shares during the last quarter. PVG Asset Management Corp purchased a new stake in shares of CalciMedica during the third quarter worth $67,000. Millennium Management LLC boosted its position in CalciMedica by 30.5% during the fourth quarter. Millennium Management LLC now owns 72,057 shares of the company’s stock valued at $255,000 after purchasing an additional 16,824 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in CalciMedica by 51.2% in the third quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock valued at $295,000 after purchasing an additional 22,525 shares in the last quarter.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.